Cell Source Reports Severe Going Concern Warning, Critically Low Cash, and Extensive Past-Due Debt
summarizeSummary
Cell Source, Inc. filed its Q1 2025 report, revealing a severe going concern warning, a critically low cash balance of $1,240, and over $17 million in past-due notes payable, despite recent highly dilutive financing efforts.
check_boxKey Events
-
Severe Going Concern Warning
The company explicitly states substantial doubt about its ability to continue as a going concern, citing a net loss of $1.48 million, cash used in operations of $600,000, and a working capital deficiency of $20.1 million for Q1 2025.
-
Critically Low Cash Position
Cash on hand as of March 31, 2025, was only $1,240, down from $74,631 at year-end 2024, indicating an unsustainable cash burn rate.
-
Extensive Past-Due Debt
As of March 31, 2025, and through the filing date, the company had approximately $17.4 million in notes and convertible notes payable that were past due, representing a significant portion of its market capitalization.
-
Highly Dilutive Financing Activities
Subsequent to Q1 2025, the company raised approximately $3.25 million through various notes payable, Series B Convertible Preferred Stock, and common stock issuances, all accompanied by significant warrant grants and original issue discounts.
auto_awesomeAnalysis
Cell Source, Inc.'s Q1 2025 report highlights a dire financial situation, reiterating a going concern warning. The company's cash balance has plummeted to a critically low $1,240, and it faces over $17 million in past-due notes payable. While the company secured approximately $3.25 million in new financing subsequent to the quarter, these funds were raised through highly dilutive issuances of common stock, convertible preferred stock, and warrants. Furthermore, the automatic conversion of Series A and C Preferred Stock into over 18.7 million common shares significantly increases the outstanding share count, exacerbating dilution for existing shareholders. The company's ability to continue operations is in substantial doubt, dependent on further capital raises or debt conversions, which have historically been highly dilutive.
At the time of this filing, CLCS was trading at $0.82 on OTC in the Life Sciences sector, with a market capitalization of approximately $55.7M. The 52-week trading range was $0.18 to $2.25. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.